Core 1 will provide an In silico framework (i) for modeling the systemic administration of therapeutic agents to solid tumors, their transport properties, and their efficacy in controlling tumor growth and (ii) for the 'rational design'of injectable nano-sized particulate systems (nPSs). The mathematical tools will be multi-scale and multi-physics spanning from the analysis of particulate transport within the vascular compartment (sovracellular level, >10 um), to the adhesive interactions with the vascular walls and macrophages/Kuppfer cells within the liver sinusoids (cellular level, >1 um and <10 um);to the passive translocation across the vascular endothelium and Gl epithelial layers (sub-cellular level, <1 um), down to the cellular internalization and intracellular transport (sub-cellular level, ? 1 um). This core is composed by modules, highly integrated one with the other the other core. Core 1 is co-lead by Drs. Cristini and Decuzzi with the collaboration of Dr. Ferrari and Dr. Macklin. Dr. Cristini (Ph.D. Chemical Engineering, FAAN) is an Associate Professor of Biomedical Engineering and Health Information Sciences at the University of Texas Health Science Center and provides multiscale modeling expertise. Dr. Decuzzi (Ph.D. Mechanical Engineering) is an Associate Professor of Mechanical and Biomedical Engineering at the University of Texas Health Science Center and the Center for Bio/Nanotechnology and Engineering for Medicine at the University of Magna Graecia (In Italy). Dr. Ferrari (Ph.D. Mechanical Engineering) is professor of Professor and Director of the Division of Nanomedicine and Professor of Internal Medicine in the Cardiology Division of The University of Texas Health Science Center, Deputy Chairman of the Department of Biomedical Engineering at the University of Texas. Dr. Macl

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (O1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Methodist Hospital Research Institute
United States
Zip Code
Pulikkathara, Merlyn; Mark, Colette; Kumar, Natasha et al. (2017) Sucrose modulation of radiofrequency-induced heating rates and cell death. Converg Sci Phys Oncol 3:
Näkki, Simo; Martinez, Jonathan O; Evangelopoulos, Michael et al. (2017) Chlorin e6 Functionalized Theranostic Multistage Nanovectors Transported by Stem Cells for Effective Photodynamic Therapy. ACS Appl Mater Interfaces 9:23441-23449
Mackeyev, Yuri; Mark, Colette; Kumar, Natasha et al. (2017) The influence of cell and nanoparticle properties on heating and cell death in a radiofrequency field. Acta Biomater 53:619-630
Lapin, Norman A; Krzykawska-Serda, Martyna; Dilliard, Sean et al. (2017) The effects of non-invasive radiofrequency electric field hyperthermia on biotransport and biodistribution of fluorescent [60]fullerene derivative in a murine orthotopic model of breast adenocarcinoma. J Control Release 260:92-99
Khalid, Ayesha; Persano, Stefano; Shen, Haifa et al. (2017) Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert Opin Drug Deliv 14:865-877
Samuelsson, Emma; Shen, Haifa; Blanco, Elvin et al. (2017) Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces 158:356-362
Venuta, Alessandro; Wolfram, Joy; Shen, Haifa et al. (2017) Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B 5:207-219
Wolfram, Joy; Nizzero, Sara; Liu, Haoran et al. (2017) A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci Rep 7:13738
Liang, Kai; Liu, Fei; Fan, Jia et al. (2017) Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng 1:
Borsoi, Carlotta; Leonard, Fransisca; Lee, Yeonju et al. (2017) Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 403:296-304

Showing the most recent 10 out of 243 publications